Drug Trial Radar · NCT02563548
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Oct 22, 2015
Primary completion
Mar 26, 2019
Study completion Mar 26, 2019
Sponsor
- Lead sponsor
- Halozyme TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 30, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b study evaluating a combination of PEGPH20 and pembrolizumab in hyaluronan-high (HA-high) participants with relapsed/refractory non-small cell lung cancer (NSCLC) and HA-high participants with relapsed/refractory gastric adenocarcinoma (GAC).
Conditions
- NSCLC
- Gastric Cancer
Interventions
PEGPH20Drug
PEGPH20 will be administered as an intravenous (IV) infusion as per the dose schedule specified in the arm description.
PembrolizumabDrug
Pembrolizumab will be administered as an IV infusion as per the dose schedule specified in the arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Escalation Phase: Number of Participants With Dose-Limiting Toxicity (DLT)Time frame: Cycle 1 (21 days)
- Dose-Escalation Phase: Maximum Tolerated Dose (MTD) of PEGPH20 in Combination With PembrolizumabTime frame: Cycle 1 (21 days)
- Dose Escalation Phase: Recommended Phase 2 Dose (RP2D) of PEGPH20 in Combination With PembrolizumabTime frame: Cycle 1 (21 days)
- Dose Expansion Phase: Objective Response Rate (ORR): Percentage of Participants With Objective Response, as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Cycle 1 Day 1 of dose-expansion phase until death, disease progression, or unacceptable toxicity (maximum exposure: 60 weeks for GAC, and 46 weeks for NSCLC)
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mayo Clinic, Scottsdale, Arizona
Scottsdale, Arizona
California Cancer Associates for Research and Excellence - Encinitas
Encinitas, California
University of California San Diego - Moores Cancer Center
La Jolla, California
St. Joseph's Hospital
Orange, California
University of California - Davis
Sacramento, California
St. Joseph's Hospital
Santa Rosa, California
Innovative Clinical Research
Whittier, California
University of Colorado Denver University of Colorado Anschutz Medical Campus
Aurora, Colorado
Georgetown University Medical Center
Washington D.C., District of Columbia
Holy Cross Hospitals
Fort Lauderdale, Florida
University of Miami/Sylvester Cancer Center
Miami, Florida
Cleveland Clinic Florida
Weston, Florida
Emory University
Atlanta, Georgia
University of Chicago
Chicago, Illinois
Ochsner Clinic Foundation
New Orleans, Louisiana
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland
Barbara Ann Karmanos Cancer Center
Detroit, Michigan
Washington University School of Medicine
St Louis, Missouri
New Jersey Hematology Oncology Associates
Brick, New Jersey
University of Rochester
Rochester, New York
Gabrail Cancer Center
Canton, Ohio
Cleveland Clinic
Cleveland, Ohio
Ohio State University
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
Mary Crowley Cancer Research Center
Dallas, Texas
Virginia Cancer Specialists, PC
Fairfax, Virginia
Swedish Health Services
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.